|Bid||386.00 x N/A|
|Ask||296.90 x N/A|
|Day's Range||310.00 - 367.00|
|52 Week Range||160.00 - 704.90|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Jun 03, 2012|
|1y Target Est||N/A|
DÜSSELDORF, Germany and TEL AVIV, Israel , April 1, 2020 /CNW/ -- Neuraxpharm, a leading European specialty pharmaceutical company, together with Panaxia Labs Israel ("Panaxia Israel") (PNAX.TA), Israel's largest medical cannabis manufacturer, today announced it is starting to market medical cannabis products, becoming the first European pharmaceutical company to include medical cannabis products in its portfolio. Neuraxpharm, which specializes in pharmaceutical products for the central nervous system (CNS), chose Panaxia Labs Israel, Israel's largest medical cannabis manufacturer, as its partner in a business collaboration for the manufacture, commercialization and distribution of advanced medical cannabis products in Germany , Europe's largest and fastest-growing medical cannabis market.
TEL AVIV, Israel and ALBUQUERQUE, N.M., March 23, 2020 /PRNewswire/ -- Panaxia (TelAviv: PNAX), the largest manufacturer and distributor of pharmaceutical cannabis products in Israel, and its partner Ultra Health have announced the arrival in Israel of the first shipment of hemp extract, having been awarded a first-of-its-kind permit to export cannabis oil from the US to Israel.